| 000 | 00928 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250518071541.0 | ||
| 264 | 0 | _c20191125 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMc1913157 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZweck, Elric | |
| 245 | 0 | 0 |
_aOral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _c11 2019 |
||
| 300 |
_a2075-2076 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aDiabetes Mellitus, Type 2 |
| 650 | 0 | 4 | _aGlucagon-Like Peptides |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHypoglycemic Agents |
| 700 | 1 | _aWestenfeld, Ralf | |
| 700 | 1 | _aSzendroedi, Julia | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 381 _gno. 21 _gp. 2075-2076 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMc1913157 _zAvailable from publisher's website |
| 999 |
_c30333004 _d30333004 |
||